You are here

A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Bioskin GmbH
Hamburg, , 20095 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Psoriasis Vulgaris
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Healthy male and/or female subjects age 18 years and older, inclusive. Healthy is
defined as no clinically relevant abnormalities identified by a detailed medical
history, full physical examination, including blood pressure and pulse rate
measurement, 12 lead ECG or clinical laboratory tests.

- Subjects with psoriasis vulgaris in a chronic stable phase and with a plaque area of
mild to moderate severity sufficient for six treatment fields located in up to three
plaque areas.

- The target lesion(s) should be on the trunk or extremities (excluding palms/soles).
Psoriatic lesions on the knees or elbows are not to be used as a target lesion.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Subjects with psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica,
psoriasis arthropathica and pustular psoriasis.

- Treatment with any systemic medications which in the opinion of the investigator might
counter or influence the trial aim (including anti psoriasis medications, eg,
corticosteroids, cytostatics or retinoids) or medications which are known to provoke
or aggravate psoriasis (eg, beta blocker, anti malarial drugs, lithium) or
phototherapy/psoralen+UVA (PUVA) within 4 weeks preceding the treatment phase of the
trial and during the trial.

- Treatment with any locally acting medications (including anti-psoriasis medications
like vitamin D analogues, dithranol) within 4 weeks of the treatment phase.

NCT02193815
Pfizer
Completed
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A 12 Day Study To Evaluate A Topical Drug To Treat Plaque Psoriasis
A Phase 1, Single- Center, Randomized, Double-blind, Vehicle And Active Comparator-controlled Trial To Evaluate The Antipsoriatic Activity And Safety Of A Topically Applied Pf-06263276 Formulation In A Psoriasis Plaque Test
This is a vehicle and comparator controlled Proof of Mechanism (PoM) trial to evaluate the effect on psoriasis disease activity and safety of topically applied PF 06263276 in subjects with psoriasis vulgaris.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Psoriasis Vulgaris
  • Drug: PF06263276
    4% PF 06263276 solution Daily dosage: approximately 8 mg PF 06263276 QD
  • Other: Vehicle
    Active ingredient-free vehicle to 4% solution
  • Drug: 2%Tofacitinib Ointment
    Daily Dosage: approximately 4 mg tofacitinib
  • Other: Vehicle
    Active ingredient-free vehicle to 2% Ointment
  • Drug: Daivonex
    Daivonex solution (50 ug/ml Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
  • Drug: Daivonex Ointment
    Daivonex ointment (50 ug/g Calcipotriol) Daily Dosage of calcipotriol: approximately 0.01 mg
Experimental: One Arm
Study treatments 1-6 Study drug, vehicle, Tofacitinib, vehicle, Daivonex solution and ointment
Interventions:
  • Drug: PF06263276
  • Other: Vehicle
  • Drug: 2%Tofacitinib Ointment
  • Other: Vehicle
  • Drug: Daivonex
  • Drug: Daivonex Ointment
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
15
February 2015
February 2015   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male and/or female subjects age 18 years and older, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse rate measurement, 12 lead ECG or clinical laboratory tests.
  • Subjects with psoriasis vulgaris in a chronic stable phase and with a plaque area of mild to moderate severity sufficient for six treatment fields located in up to three plaque areas.
  • The target lesion(s) should be on the trunk or extremities (excluding palms/soles). Psoriatic lesions on the knees or elbows are not to be used as a target lesion.

Exclusion Criteria:

  • Subjects with psoriasis guttata, psoriasis punctata, psoriasis erythrodermatica, psoriasis arthropathica and pustular psoriasis.
  • Treatment with any systemic medications which in the opinion of the investigator might counter or influence the trial aim (including anti psoriasis medications, eg, corticosteroids, cytostatics or retinoids) or medications which are known to provoke or aggravate psoriasis (eg, beta blocker, anti malarial drugs, lithium) or phototherapy/psoralen+UVA (PUVA) within 4 weeks preceding the treatment phase of the trial and during the trial.
  • Treatment with any locally acting medications (including anti-psoriasis medications like vitamin D analogues, dithranol) within 4 weeks of the treatment phase.
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT02193815
B5391003
2014-000068-16 ( EudraCT Number )
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2016

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now